SUBCHONDRAL BONE MARROW LESION CEMENT OK’D IN EUROPE (Orthopedics This Week)
Graftys Website
Graftys, S.A., a company founded in 2005 and based in the university town of Aix-En-Provence, France, has a line of innovative biomaterials has received authorization to commercialize two new cements to treat bone marrow lesions caused by traumatic injury.
The new cements are brandnamed Graftys HBS and Graftys Quickset. Both, say the company, are injectable and resorbable calcium phosphate cements. Their indicated use is for treating subchondral bone marrow lesions. Also known as bone marrow edema, the ailment results in loss of bone volume, micro fractures and a decline of mechanical strength of the subchondral bone above or below the knee joint
“When these bone marrow lesions occur in the subchondral condyle or under the tibial plateau, they can create pain and lead to total knee replacement once traditional treatments fail,” said Jean-Marc Ferrier, Vice President of Clinical and Regulatory Affairs, Graftys S.A. “This new surgical treatment, which involves minimally invasive injection of calcium phosphate cement, under radiographic guidance, can provide orthopedic surgeons with a new and...
